SciThera is a San Diego biotechnology company developing antibody drug conjugates for cancer and autoimmune diseases. Its work builds on antibody engineering expertise: in 2025, it licensed antibody-library assets from Inhibrx and took over an agreement with NorthStar Medical Technologies to develop cancer radiopharmaceuticals. Founded by former Inhibrx chief scientific officer Brendan Eckelman, the company is backed by Luma Group, Alta Partners and Venrock. Its therapeutic targets and detailed pipeline remain undisclosed publicly.
